Cohance Lifesciences Financial Results

Q: What are the Net Sales of Cohance Lifesciences in the financial year 2026?

For FY 2026 , Cohance Lifesciences recorded Net Sales of ₹ 2268.55 crores .This figure helps in determining the company’s true revenue after deducting discounts, returns, and allowances from Gross sales.

Q: What is the Profit Before Tax (PBT) of Cohance Lifesciences in 2026?

In FY 2026 , Cohance Lifesciences posted a Profit Before Tax of ₹ 207.04 crores It helps to understand whether a company is efficient enough to manage its costs and generate income before eliminating taxes.

Q: What is the Net Profit of Cohance Lifesciences for 2026?

Cohance Lifesciences recorded a Net Profit of ₹ 150.12 crores in FY 2026 . It is a key indicator of profitability as it gives a more accurate picture of a company’s financial health by considering all costs associated with the business.

Q: What is the Face Value of Cohance Lifesciences?

The Face Value of Cohance Lifesciences shares is 1 .It indicates the initial capital raised by the company by issuing shares. Face value can determine a stocks current market value at the time of dividends, bonuses, or stock splits.

Q: What is the PAT Margin (PATM%) of Cohance Lifesciences in 2026?

In FY 2026 , the PAT Margin of Cohance Lifesciences is 6.62 % . This metric provides insights into the company's efficiency in generating profits after paying taxes.

BSE Code: 543064|NSE Symbol:COHANCE|ISIN: INE03QK01018

428.9 -0.5(-0.12)

Open (Rs) 428.45

Close (Rs) 429.4

High (Rs) 430.55

Low (Rs) 424.1

Face Value1

Market Capital (Cr.)16408.3

Daily Volume280245

Life Time High1121.15

Life Time Low266.7

52 Week High1121.15

52 Week Low266.7

Results

Consolidated

IN CR	MAR 2026	MAR 2025	MAR 2024	MAR 2023	MAR 2022	MAR 2021
Net Sales	2,268.55	1,197.58	1,051.35	1,340.33	1,320.22	1,009.72
Total Expenditure	1,841.56	822.38	645.54	773.80	740.80	569.24
PBIDT (Excl OI)	426.99	375.20	405.81	566.53	579.43	440.48
Other Income	34.09	58.56	61.91	46.36	92.38	14.24
Operating Profit	461.08	433.76	467.72	612.90	671.81	454.72
Interest	37.24	12.35	7.45	5.44	6.23	9.14
Exceptional Items	-29.47	0.00	0.00	0.00	0.00	0.00
PBDT	394.37	421.41	460.27	607.46	665.57	445.57
Depreciation	187.33	77.49	54.60	47.73	39.10	31.64
Profit Before Tax	207.04	343.92	405.67	559.73	626.48	413.94
Tax	56.92	79.15	105.39	148.44	213.79	105.33
Provisions and contingencies	0.00	0.00	0.00	0.00	0.00	0.00
Profit After Tax	150.12	264.77	300.28	411.29	412.69	308.61
Extraordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
Prior Period Expenses	0.00	0.00	0.00	0.00	0.00	0.00
Other Adjustments	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit	150.12	264.77	300.28	411.29	412.69	308.61
Equity Capital	38.26	25.46	25.46	25.46	25.46	25.46
Face Value (IN RS)	1.00	1.00	1.00	1.00	1.00	1.00
Reserves	3,873.03	1,671.12	2,025.21	1,709.73	1,501.72	1,155.35
Basic Eps After Extraordinary Items	4.68	10.52	11.80	16.16	17.83	14.23
Basic Eps Before Extraordinary Items	4.68	10.52	11.80	16.16	17.83	14.23
No of Public Share Holdings	0.00	0.00	0.00	0.00	0.00	0.00
% of Public Share Holdings	0.00	0.00	0.00	0.00	0.00	0.00
PBIDTM% (Excl OI)	18.82	31.33	38.60	42.27	43.89	43.62
PBIDTM%	20.32	36.22	44.49	45.73	50.89	45.03
PBDTM%	17.38	35.19	43.78	45.32	50.41	44.13
PBTM%	9.13	28.72	38.59	41.76	47.45	41.00
PATM%	6.62	22.11	28.56	30.69	31.26	30.56

FAQs

What are the Net Sales of Cohance Lifesciences in the financial year 2026?

For FY 2026, Cohance Lifesciences recorded Net Sales of ₹2268.55 crores.This figure helps in determining the company’s true revenue after deducting discounts, returns, and allowances from Gross sales.

What is the Operating Profit of Cohance Lifesciences in 2026?

The Operating Profit of Cohance Lifesciences for FY 2026 is ₹461.08 crores. With this amount, one can assess the profits derived from the company’s core (or primary) operations, excluding interest and taxes.

What is the Profit Before Tax (PBT) of Cohance Lifesciences in 2026?

In FY 2026, Cohance Lifesciences posted a Profit Before Tax of ₹207.04 croresIt helps to understand whether a company is efficient enough to manage its costs and generate income before eliminating taxes.

What is the Net Profit of Cohance Lifesciences for 2026?

Cohance Lifesciences recorded a Net Profit of ₹150.12 crores in FY 2026. It is a key indicator of profitability as it gives a more accurate picture of a company’s financial health by considering all costs associated with the business.

What is the Face Value of Cohance Lifesciences?

The Face Value of Cohance Lifesciences shares is 1.It indicates the initial capital raised by the company by issuing shares. Face value can determine a stocks current market value at the time of dividends, bonuses, or stock splits.

What is the PAT Margin (PATM%) of Cohance Lifesciences in 2026?

In FY 2026, the PAT Margin of Cohance Lifesciences is 6.62 %. This metric provides insights into the company's efficiency in generating profits after paying taxes.

How to open a Demat Account with Anand Rathi to invest in Cohance Lifesciences?

Open a Demat Account with Anand Rathi using the following steps:

1. Enter your basic details in the form.
2. Upload ID proof, PAN card, and bank details.
3. Complete eKYC online.
4. Start investing in Cohance Lifesciences using our TradeMobi App or Web Trading Platform.